Id: | acc0697 |
Group: | 1sens |
Protein: | FOXM1 |
Gene Symbol: | FOXM1 |
Protein Id: | Q08050 |
Protein Name: | FOXM1_HUMAN |
PTM: | ubiquitination |
Site: | unclear |
Site Sequence: | |
Disease Category: | Cancer |
Disease: | Pancreas Cancer |
Disease Subtype: | PDAC |
Disease Cellline: | BxPC-3 |
Disease Info: | |
Drug: | gemcitabine |
Drug Info: | "Gemcitabine is a pyrimidine nucleoside analog antimetabolite and antineoplastic agent that inhibits DNA synthesis and repair, leading to autophagy and apoptosis, and is used in the treatment of various solid tumors including non-small cell lung cancer, pancreatic cancer, breast cancer, and ovarian cancer. " |
Effect: | enhance |
Effect Info: | "Knockdown of UCHL3 increased the ubiquitination of FOXM1, thereby enhancing the turnover of FOXM1 and promoting the sensitivity of pancreatic cancer cells to gemcitabine." |
Note: | |
Score: | 5.0 |
Pubmed(PMID): | 31598398 |
Sentence Index: | 31598398_9 |
Sentence: | "Furthermore, knockdown of UCHL3 increased FOXM1 ubiquitination, which enhanced FOXM1 turnover and promoted pancreatic cancer cells' sensitivity to gemcitabine." |
Sequence & Structure:
MKTSPRRPLILKRRRLPLPVQNAPSETSEEEPKRSPAQQESNQAEASKEVAESNSCKFPAGIKIINHPTMPNTQVVAIPNNANIHSIITALTAKGKESGSSGPNKFILISCGGAPTQPPGLRPQTQTSYDAKRTEVTLETLGPKPAARDVNLPRPPGALCEQKRETCADGEAAGCTINNSLSNIQWLRKMSSDGLGSRSIKQEMEEKENCHLEQRQVKVEEPSRPSASWQNSVSERPPYSYMAMIQFAINSTERKRMTLKDIYTWIEDHFPYFKHIAKPGWKNSIRHNLSLHDMFVRETSANGKVSFWTIHPSANRYLTLDQVFKPLDPGSPQLPEHLESQQKRPNPELRRNMTIKTELPLGARRKMKPLLPRVSSYLVPIQFPVNQSLVLQPSVKVPLPLAASLMSSELARHSKRVRIAPKVLLAEEGIAPLSSAGPGKEEKLLFGEGFSPLLPVQTIKEEEIQPGEEMPHLARPIKVESPPLEEWPSPAPSFKEESSHSWEDSSQSPTPRPKKSYSGLRSPTRCVSEMLVIQHRERRERSRSRRKQHLLPPCVDEPELLFSEGPSTSRWAAELPFPADSSDPASQLSYSQEVGGPFKTPIKETLPISSTPSKSVLPRTPESWRLTPPAKVGGLDFSPVQTSQGASDPLPDPLGLMDLSTTPLQSAPPLESPQRLLSSEPLDLISVPFGNSSPSDIDVPKPGSPEPQVSGLAANRSLTEGLVLDTMNDSLSKILLDISFPGLDEDPLGPDNINWSQFIPELQ
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
- | - | D | Gastric cancer | Ubiquitination | 37288663 |
- | - | D | Pancreatic cancer | Ubiquitination | 35614040 |
- | - | P | Glioma/adult gliomas | Phosphorylation | 23404835 |
- | - | U | Breast cancer | Phosphorylation | 36795481 |
- | - | U | Basal-like breast cancer | Ubiquitination | 30865895 |
- | - | U | Pancreatic cancer | Ubiquitination | 30352219 |
- | - | U | Renal cell carcinoma | Ubiquitination | 32257108 |
- | - | U | Pancreatic cancer | Ubiquitination | 31598398 |
- | - | U | Breast cancer | Ubiquitination | 36119839 |
- | - | U | Cervical cancer | Ubiquitination | 34825342 |
- | - | U | Pancreatic cancer | Ubiquitination | 34584067 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.